However, the use of products derived from large blood donor pools resulted in a significant number of people with

bleeding disorders becoming infected with blood-borne viruses such as HCV and HIV in the 1980s, with infection rates of up to 60–70% seen among the severe haemophilia population [61, 62]. The widespread transmission of blood-borne pathogens in blood-derived products had a significant impact on the haemophilia www.selleckchem.com/products/midostaurin-pkc412.html community and resulted in a drive for continuous improvement in the safety of replacement factor concentrates. Methods for improving safety include enhanced detection of infectious agents through assays used to screen donors and products, and better methods of pathogen removal/inactivation. In addition, immunoassays have evolved to become more sensitive and specific in the quantification

of the molecule of interest, as seen in the HIV immunoassays of the 1980s. This has led to a reduced risk of transmission with current estimates of <1 per 1 million transfusions [63]. Despite these improvements in detection and elimination of pathogens, transfusion-transmitted emerging infectious diseases (TT-EIDs) should not be overlooked [64]. The emergence of new infectious diseases, including TT-EIDs, is unpredictable, but an average of 5.3 new viruses have been discovered each year from 1940 to 2004, an increase which looks set to continue, and may have an impact on the future safety of plasma-derived concentrates [63]. This rise is believed to be due, in part, to environmental factors, such as climate change, and increased find more international travel, encouraging new and varied interactions between a pathogen and its host, which may affect the pathogen’s ability to survive in different environments [63, 64]. In response, the American Association of Blood Banks (AABB), a US-based professional body

involved in the field of transfusion medicine MCE公司 and cellular therapies, has developed a ‘toolkit’ initiative as a system to assess the potential impact of EIDs on blood safety. This toolkit includes methods of identifying, monitoring, evaluating and developing interventions for EIDs. To date, the AABB has provided fact sheets on 68 TT-EIDs that include information such as the presence of the agent in the blood, the route of transmission and clinical symptoms [63]. Despite improved pathogen screening and elimination methods, rare variants of certain viruses have still been known to occur which may have escaped immediate attention, for example, through false-negative nucleic acid amplification technique [65] and false-negative serological testing in hepatitis B [66]. Similarly, some cases only became widely recognised several years after initial manifestation, such as PARV4 seroconversion in which high rates of infection were seen in haemophilia patients compared to control populations [67].